186393-22-6

Basic information

• Product Name: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate
• Synonyms: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate;rel-(3R,4S)-tert-Butyl 3,4-dihydroxypyrrolidine-1-carboxylate;cis-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate;tert-Butyl (3R,4S)-3,4-dihydroxypyrrolidine-1-carboxylate;tert-butyl-cis-3,4-dihydroxypyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-, 1,1-dimethylethyl ester, (3R,4S)-rel-
• CAS NO: 186393-22-6
• Molecular Formula: C9H17NO4
• Molecular Weight: 203.23558
• Mol File: 186393-22-6.mol
• Article Data: 38

Chemical Properties

• Boiling Point: 300.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.262±0.06 g/cm3(Predicted)
• PKA: 13.91±0.40(Predicted)
• CAS DataBase Reference: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(186393-22-6)
• EPA Substance Registry System: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(186393-22-6)

Safety Data

• Hazardous Substances Data: 186393-22-6(Hazardous Substances Data)

Usage

Description

(3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate is a heterocyclic derivative characterized by its unique molecular structure and functional groups. It is a versatile compound with potential applications in various industries due to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
(3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and functional groups make it a valuable building block in the development of new pharmaceutical compounds, contributing to the advancement of drug discovery and innovation.
Used in Chemical Synthesis:
(3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate is also used as a key intermediate in the synthesis of various chemical compounds. Its reactivity and structural features allow for the creation of a wide range of products, making it a valuable asset in the field of chemical synthesis and research.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 90365-74-5 (3S,4S)-(+)-1-benzyl-3,4-pyrrolidinediol 
• 1428671-12-8 (3S,4S)-1-(tert-butoxycarbonyl)-3,4-pyrrolidinediyl diacetate 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 86953-79-9 tert-butyl pyrrolidine-1-carboxylate 
• 114214-49-2 rac-tert-butyl (1R,5S)-6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 4248-19-5 tert-butyl carbazate 
• 151259-38-0 tert-butyl diallylcarbamate 
• 60138-51-4 tert-butyl 2,5-dihydropyrrole 
• 163439-82-5 (3R,4R)-1-benzyl-3,4-pyrrolidinediol 
• 186393-31-7 (3R,4R)-pyrrolidine-3,4-diol 
• 762-75-4 tert-butyl formate 
• 90481-32-6 (3S,4S)-pyrrolidine-3,4-diol 

Downstream Products

• 56074-20-5 N-((tert-butyloxy)carbonyl)iminodiacetic acid 
• 503552-68-9 (3R,4R)-1-N-tert-butyloxycarbonyl-3,4-diaminopyrrolidine 
• 276862-76-1 (3S,4S)-pyrrolidine-3,4-diol hydrochloride 
• 148214-86-2 tert-butyl (3R,4R)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 372482-11-6 tert-butyl (3S,4S)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 148214-86-2 rac-tert-butyl (3R,4S)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 945217-60-7 tert-butyl (3R,4S)-3,4-diaminopyrrolidine-1-carboxylate 
• 694439-03-7 tert-butyl (4aR,7aS)-hexahydro-2H-[1,4]dioxino[2,3-c]pyrrole-6-carboxylate 
• 694439-03-7 tert-butyl (4aS,7aS)-hexahydro-6H-[1,4]dioxino[2,3-c]pyrrolidine-6-carboxylate 

Relevant articles and documents

Discovery of 1-pyrimidinyl-2-aryl-4,6-dihydropyrrolo [3,4-d]imidazole-5(1H)-carboxamide as a novel JNK inhibitor

We designed and synthesized 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo [3,4-d] imidazole-5(1H)-carboxamide derivatives as selective inhibitors of c-Jun-N-terminal Kinase 3 (JNK3), a target for the treatment of neurodegenerative diseases. Based on the compounds found in previous studies, a novel scaffold was designed to improve pharmacokinetic characters and activity, and compound 18a, (R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydro pyrrolo [3,4-d]imidazole-5(1H)-carboxamide, showed the highest IC50 value of 2.69 nM. Kinase profiling results also showed high selectivity for JNK3 among 38 kinases, having mild activity against JNK2, RIPK3, and GSK3β, which also known to involve in neuronal apoptosis.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

SUBSTITUTED TRICYCLICS AND METHOD OF USE

The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj?gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).